मुख्यपृष्ठ › मल्टिपल मायलोमा › कोलोराडो › Denver
Denver, CO मधील मल्टिपल मायलोमा साठी क्लिनिकल ट्रायल्स
Denver आणि आजूबाजूच्या ठिकाणी (सुमारे 30 मैलांच्या आत) मल्टिपल मायलोमा साठी 27 अभ्यास सहभागी शोधत आहेत. कोण सहभागी होऊ शकते आणि अभ्यास संघाशी संपर्क कसा साधावा हे पाहण्यासाठी अभ्यास उघडा.
अधिकृत अभ्यास मजकूर (इंग्रजी)
अभ्यासासाठी सहभागी शोधत आहात? हे पृष्ठ शीर्षस्थानी दर्शवा — 30 दिवसांसाठी $99 →
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
निवड सुरू आहेफेज 2
- Colorado Blood Cancer Institute, Denver
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
निवड सुरू आहेफेज 1
- Colorado Blood Cancer Institute /ID# 280275, Denver
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
निवड सुरू आहेफेज 3
- Research Site, Denver
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
निवड सुरू आहेफेज 1
- Colorado Blood Cancer Institute, Denver
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 3
- Colorado Blood Cancer Institute, Denver
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
निवड सुरू आहेफेज 2
- Colorado Blood Cancer Institute, Denver
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
निवड सुरू आहेफेज 1
- Research Site, Denver
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
निवड सुरू आहेफेज 1
- Colorado Blood Cancer Institute, Denver
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 3
- Colorado Blood Cancer Institute, Denver
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
निवड सुरू आहेफेज 2/3
- Colorado Blood Cancer Institute /ID# 279080, Denver
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
निवड सुरू आहेफेज 3
- CBCI, Colorado Blood Cancer Institute, Denver
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 1
- Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 2
- Colorado Blood Cancer Institute, Denver
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
निवड सुरू आहेफेज 2
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 1/2
- Research Site, Denver
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
निवड सुरू आहेफेज 1/2
- Colorado Blood Cancer Institute/SCRI, Denver
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
निवड सुरू आहेफेज 1/2
- Research Site, Denver
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
निवड सुरू आहेफेज 3
- Research Site, Denver
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
निवड सुरू आहेफेज 1/2
- Colorado Blood Cancer Institute /ID# 273129, Denver
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
निवड सुरू आहेफेज 2
- Colorado Blood Cancer Institute, Denver
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
निवड सुरू आहेफेज 3
- Colorado Blood Cancer Institute, Denver
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
निवड सुरू आहेफेज 2
- Colorado Blood Cancer Institute, Denver
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
निवड सुरू आहेफेज 1/2
- Colorado Blood Cancer Institute/SCRI, Denver
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 1
- Colorado Blood Cancer Institute /ID# 273751, Denver
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
निवड सुरू आहेफेज 2
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
निवड सुरू आहेफेज 1/2
- Colorado Blood Cancer Institute, Denver
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
निवड सुरू आहेफेज 1
- Colorado Blood Cancer Institute, Denver
इतर शहरांतील मल्टिपल मायलोमा ट्रायल्स
- New York City, NY60 अभ्यास
- Boston, MA42 अभ्यास
- Atlanta, GA41 अभ्यास
- Houston, TX38 अभ्यास
- Durham, NC37 अभ्यास
- Nashville, TN32 अभ्यास
- Rochester, MN24 अभ्यास
- St. Louis, MO24 अभ्यास
- Columbus, OH24 अभ्यास
- Baldwin Park, CA23 अभ्यास
- Chicago, IL22 अभ्यास
- Seattle, WA22 अभ्यास
Denver मधील इतर अभ्यास
- मेटास्टॅटिक कर्करोग29 अभ्यास
- स्तनाचा कर्करोग28 अभ्यास
- नॉन-स्मॉल सेल लंग कॅन्सर27 अभ्यास
- कोलोरॅक्टल कॅन्सर23 अभ्यास
- प्रोस्टेट कर्करोग19 अभ्यास
- मेलेनोमा19 अभ्यास
- कर्करोग (सर्व प्रकार)18 अभ्यास
- अंडाशयाचा कर्करोग16 अभ्यास
- फुफ्फुसाचा कॅन्सर16 अभ्यास
- एंडोमेट्रियल कर्करोग15 अभ्यास
- नॉन-हॉजकिन लिम्फोमा14 अभ्यास
- स्वादुपिंडाचा कर्करोग13 अभ्यास
ClinicalTrials.gov वरून, 5 ऑक्टो, 2026 रोजी मिळालेली माहिती. प्रत्येक अभ्यासासाठी पात्रतेचे निकष वेगळे असतात; अभ्यास संघ ठरवतो की कोण सहभागी होऊ शकते.